Our Vision – Innovita Research

Nature has developed plenty of smart mechanisms to help us to go by the way of evolution, reproduction and limited life span. These are related very closely, so our main task is to find solution for this riddle by using abilities of biological systems to help us to drive this mode to life span prolongation by smart technological approach. By going deep into biological systems, we found many interesting points in some pathogenesis of incurable diseases, so we applied our knowledge how to make body heal autoimmune, degenerative diseases by using its own tissue, usually blood and immune system components. Here we developed a number of technologies to overcome disbalances of biological systems, preparing drugs from the own tissues and cells of the patient. Personalized approach to treat a disease is the main target in our technologies.

We started more than fifteen years ago as a company mainly interested in aging problems and research in a field of anti-aging medicine. Everything has begun from collection and analysis of all information about aging process and how it could be managed. From the very first beginning we consider aging as a disease, which is caused by programmed processes in the cells, tissues and organs. We can start from the error prone DNA replication system, which eventually drives all the body into cascade of replication errors leading to molecular mechanism disregulation and triggering of regenerative problems and going deep into cell organelle dysfunctions such as Mitochondrial DNA, which is also touched by aging and needs to be repaired or replaced with the new ones, better young ones. This is not all, as there are all vital systems touched by time, and this needs to be considered when we think about smart engineering of biological systems to escape fall of the body as a complicated machine into switch off mode.

We are currently focus our activities on novel extracorporeal immunotherapeutic technologies and modalities based on autologous and allogeneic human peripheral blood components for subsequent clinical introduction and application in health care delivery systems.

Current paradigm holds that the immune system is designed to maintain antigenic homeostasis and structural integrity of the body, with human peripheral blood containing all necessary and sufficient components of the innate and acquired immunity.

Specifically, our Company has developed extracorporeal state-of-the-art technologies allowing for implementation of highly efficient control and manipulation of migrational and functional activity of various leukocyte populations (granulocytes, macrophages and lymphocytes). In particular, we established an innovative technology that significantly enhances antitumor activity of the immunocompetent cells in vivo. In addition, we performed preliminary clinical trials of another technology which up-regulates regenerative mechanisms in various tissues. The Company is vigorously pursuing other avenues of translational research, such as anti-infectious technologies.

Importantly, all the above-mentioned technologies provide a possibility for the application of autologous (i.e. from the same patient) and allogeneic (i.e. of a donor origin) immunocompetent cells; the latter possibility opens an access to the realm of fully competent immune cells with high clinical potential. We emphasize that our final leukocyte-based immunotherapeutic agents lack erythrocytes and human plasma components, thus effectively eliminating the risk of potential serious side effects and complications due to harmful interactions between natural antibodies with erythrocyte-associated antigens. The extracorporeal (i.e. out of the body, in vitro) module of cellular technologies developed in the Company allows for targeted modulation of desired functions of immunocompetent cells with specific drugs in order to achieve their maximal immunomodulating clinical effectiveness with concomitant minimal side effects.

The Company has developed an autologous T-cell immunotherapy (T-cell vaccination) protocol, which is designed to stimulate adaptive immunological mechanisms in order to prevent the development of pathological inflammatory processes. This particular technology could be effectively applied for treatment of an array of autoimmune and allergic disorders in the clinic. As our T-cell vaccination protocol has been developed to specifically and selectively inactivate pathogenic lymphocytes only, clinical application of autologous T-cell immunotherapy is not prone to serious complications, and therefore is not subject to absolute contraindications on the part of the patients.